Edwards Lifesciences (EW) Tax Provisions (2009 - 2026)

Edwards Lifesciences' Tax Provisions history runs 18 years deep, the most recent figure standing at $78.3 million for Q1 2026.

• On a quarterly basis, Tax Provisions rose 11.38% year-over-year to $78.3 million in Q1 2026; TTM through Mar 2026 was $224.9 million, a 27.71% increase from a year earlier, with the FY2025 full-year figure at $216.9 million, up 42.6% from the prior year.
• Tax Provisions climbed to $78.3 million in Q1 2026 per EW's latest filing, from $26.2 million in the prior quarter.
• Across five years, Tax Provisions topped out at $78.3 million in Q1 2026 and bottomed at $10.9 million in Q4 2022.
• The 5-year median for Tax Provisions is $52.7 million (2023), against an average of $47.6 million.
• Across the five-year window, Tax Provisions sank 73.41% in 2022 and jumped 221.5% in 2025, its largest moves.
• Year by year, Tax Provisions stood at $10.9 million in 2022, then jumped by 212.84% to $34.1 million in 2023, then soared by 32.26% to $45.1 million in 2024, then tumbled by 41.91% to $26.2 million in 2025, then soared by 198.85% to $78.3 million in 2026.
• Per Business Quant, the three latest EW Tax Provisions figures stand at $78.3 million (Q1 2026), $26.2 million (Q4 2025), and $56.1 million (Q3 2025).